Get started
Work

A Phase II Trial of Prophylactic Anakinra to Prevent Neurotoxicity in Patients Receiving Anti-CD19 CAR T-Cell Therapy for Relapsed or Refractory Lymphoma: Final Results from Cohort 2

Year: 2023
Type: conference-abstract
Source: Blood
DOI: 10.1182/blood-2023-174728
Authors: Karthik Nath, Sean M. Devlin, Craig S Sauter, Maria Lia Palomba, Gunjan L. Shah, Parastoo Bahrami Dahi, Richard J. Lin, Michael Scordo, Miguel-Angel Perales, Lori A. Leslie, Roni Shouval, Sara Bekele, Elizabeth Cathcart, Elena Mead, Bianca Santomasso, Andrei Holodny, Renier Brentjens, Isabelle Riviere, Michel Sadelain, Jae H. Park
Institutions: Memorial Sloan Kettering Cancer Center, Cleveland Clinic, Weill Cornell Medicine, Hackensack Meridian Health, Roswell Park Comprehensive Cancer Center, Takeda (United States)
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W4389231008
Cites:
Cited by: 4
Related to: 10